255results about How to "Receive treatment well" patented technology

The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.

The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.

An intravascular extracardiac pumping system for increasing perfusion through a renal artery to tissues of a patient without any component thereof being connected to the patient's heart is provided. The system includes means for pumping blood and a portion that houses the pumping means. The portion that houses the pumping means is configured to direct blood from a location upstream of the pumping means to a location within a renal artery. The pumping means and the portion that houses the pumping means are configured to be insertable into a non-primary vessel subcutaneously in an minimally-invasive procedure for positioning within the patient's vasculature.

Therapeutic agent delivery devices and methods for delivering a therapeutic agent to a target location as well as methods for determining the location of a lesion on a vessel wall are disclosed. Various embodiments disclose an expandable member comprising a drug delivery matrix for selectively delivering a therapeutic agent to a lesion on a vessel wall. The drug delivery matrix may comprise one or more sensors and an electroactive polymer for releasing the therapeutic agent. Other embodiments disclose an expandable member comprising a plurality of radially-expanding flexible walls forming a plurality of channels for selectively delivering therapeutic agent to a target area adjacent one or more of the channels. Detecting a lesion may comprise using a plurality of Hall effect sensors disposed on a distal end of a catheter.

The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and / or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.

A delivery device that includes a cutter for opening a barrier layer to provide fluid access to a dose chamber, and a diverting structure for direct air flow toward the dose chamber.

There is provided an inflatable mattress and coverlet used to reduce and treat decubitus ulcers. The mattress is an air inflatable mattress and is particularly adapted for use on a bed in a hospital, nursing home, health care facility or the like. The air inflatable mattress has a series of apertures on the top allowing small amounts of air to pass through to the underside of the coverlet. According to one aspect of the invention the coverlet is placed over the top of air inflatable mattress in the central portion thereof between the head of the bed and the foot of the bed. The coverlet is of sufficient length to extend under the weight bearing portions of the patient. The coverlet has as a first layer a moisture wicking fabric, such as a polyester, and on one side of the moisture wicking fabric there is attached a microporous polymeric member which allows air from the mattress to pass through the coverlet to the patient. Adjacent the polymeric member is another layer comprising a spacer fabric. The side edges of the coverlet form a drip edge and may be attached to the mattress by suitable means.

The tissue therapy device includes a sealant layer and a suction apparatus. The sealant layer creates a sealed enclosure between it and the surface of a patient by forming an airtight seal around an area of tissue. The suction apparatus is in fluid communication with the sealant layer and together, create a closed, reduced pressure therapy system. The suction apparatus self-creates reduced pressure by decreasing the density of air molecules underneath the sealant layer by expanding the volume of the air molecules.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 ROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 24 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 24 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

An alginate gel adsorbent to remove heavy metal ions according to the present invention is prepared by adding dropwisely 0.1-5 wt % alginate solution to a polyvalent cationic solution thereby cross-linking alginic acid with polyvalent cations. An alginate gel adsorbent containing activated carbon capable of simultaneously removing heavy metal ions and organotoxic materials, that is, activated carbon / alginate gel adsorbent, is prepared by adding dropwisely a mixed solution of 0.17-10 wt % of alginate and 0.1-10 wt % of activated carbon powder to a polyvalent cationic solution thereby cross-linking alginic acid with polyvalent cations in order to immobilize polyvalent cation to alginic acid containing activated carbon. The polyvalent cationic solution is selected from the group consisting of calcium chloride (CaCl2), strontium chloride (SrCl2), barium chloride (BaCl2) and aluminium chloride (AlCl3). A flat board or a thin membrane coated alginate gel adsorbent can be prepared by coating alginate gels onto a supporter such as paper, wood plate and textile fabrics. The alginate gel adsorbent for water purification can be applied to a water purifier as well as a process of wastewater treatment. The alginate gel coated onto a supporter is prepared by immersing a supporter in 0.05-5 wt % alginate solution so that the supporter may uniformly adsorb the alginate solution, immersing the supporter in a polyvalent cationic solution thereby forming alginate gel on the surface of the supporter, and drying the supporter formed with alginate gel thereon.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 24 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease.

This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX. The immunoconjugate may be administered at a dosage of between 1 mg / kg and 18 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg, more preferably 8 or 10 mg / kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.

Compounds useful for countering undesired toxic effects to cells, tissues or organs having formula (I) wherein: Ar is a group of formulae (i) or (ii), n is O or, when Ar has formula (i) above, then n may also be 1, R is CN, -GC(S)NH2, -C(O)NHR3 or, when R1 is 4-NO2 and R2 is H or 3-OH, then R may also be a group of formulae (iii), (iv), (v), (vi) where R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl; R1 and R2 are each independently H, OH, NO2 or, when R is CN, also CH3, F, or CF3, provided that both R1 and R2 are simultaneously H.

A continuous positive airway pressure (CPAP) apparatus for respiratory assistance of a pattern is disclosed. There is a blower having an output connectible to a ventilation mask wearable by the patient. A first pressure sensor measures blower pressure at the output of the blower, and a second pressure sensor that is connectible to the ventilation mask measures mask pressure therein. A pressure controller is connected to the first pressure sensor and the second pressure sensor, and a patient inspiratory phase and a patient expiratory phase is be detectable by the pressure controller to regulate therapeutic pressure at the patient mask, based upon pressure differentials between the mask pressure and the blower pressure.

The invention is directed to mechanisms and methods that reduce the delamination of a therapeutic agent from a stent. The mechanisms include holes (channels, wells, and other hole configurations), protrusions, sintered metal cores, clamps / staples, pins, and stainless steel shields.

The invention discloses medicine for curing rheumatoid arthritis and belongs to the technical field of medical products. The medicine is a medicine composition prepared by all natural plants, animals, mineral and other ingredients which serve as raw materials according to a certain process. The medicine has unique effects on the rheumatoid arthritis and scapulohumeral periarthritis and remarkable effects on rheumatoid arthritis, osteonecrosis of the femoral head and lumbar disc herniation. The medicine is mainly characterized by expelling wind and removing cold, clearing and activating channels and collaterals, activating blood and dissolving stasis, and relieving swelling and pain; and diseases do not recur after heal. The medicine is wide in the raw materials, low in cost, simple in preparation method and free of emission of three wastes in production.

The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.

The present invention is to provide a multiple-agents-binding compound comprising a compound having anti-HIV activity and having no affinity for cell surface protein bound together with a same or different kind of at least one compound having anti-HIV activity and having no affinity for cell surface protein, or a salt thereof, and a pharmaceutical composition for the prevention or treatment of infectious diseases of HIV or AIDS comprising said multiple-agents-binding compound.

The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX. The immunoconjugate may be administered at a dosage of between 1 mg / kg and 18 mg / kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg / kg, more preferably 8 or 10 mg / kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.

The present invention concerns compositions and methods of use of a humanized Class III anti-CEA antibody, comprising the heavy and light amino acid sequences SEQ ID NO:1 and SEQ ID NO:2. The antibody is effective to treat CEACAM5-expressing tumors, either alone or in combination with one or more therapeutic agents. Drug conjugated Class III anti-CEA antibodies, such as SN-38 or P2PDox immunoconjugates, are particularly efficacious. Surprisingly, the antibody-drug conjugates (ADCs) exhibit high anti-cancer efficacy, while exhibiting low levels of systemic toxicity that are readily treated with standard amelioration techniques. Antibodies and / or immunoconjugates comprising the amino acid sequences SEQ ID NO:1 and SEQ ID NO:2 are surprisingly efficacious for therapy of solid tumors, even when the tumor has proven resistant to standard anti-cancer therapies.